Vibrating Mesh Aerosol Generator for Neonatal Surfactant Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional non-invasive surfactant delivery techniques for infants, especially preterm infants, are inefficient and often result in acute side effects due to the inability to effectively and efficiently deliver surfactant aerosolized medicament with small enough particle sizes to penetrate the lungs.
Innovation Solution
An aerosolization system that aerosolizes medicament into particles with a mass mean aerodynamic diameter (MMAD) of less than 3 µm at a rate of at least 0.1 ml/min, synchronized with the infant's inhalations, using a vibrating mesh aerosol generator and baffles to direct airflow and minimize aerosol loss, ensuring delivery directly to the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional non-invasive aerosolization techniques are used to deliver surfactant, then the delivery method is non-invasive, but the aerosol particles are too large (4-7 μm MMAD) to effectively penetrate into the lungs
Solution Approach 1:
The patent employs a vibrating mesh aerosol generator that uses mechanical vibration to atomize surfactant solution into fine aerosol particles. The mesh vibrates at high frequency to break liquid into droplets, achieving MMAD < 3 μm while maintaining high output rates suitable for neonatal delivery
Solution Approach 2:
The invention changes key parameters including reducing particle size from 4-7 μm to < 3 μm MMAD, optimizing aerosol generation rate to ≥ 0.1 ml/min, and positioning the aerosol generator 2-8 cm from the patient interface to achieve effective pulmonary delivery
2Productivity
If aerosolized medicament is delivered continuously, then constant delivery is maintained, but medicament is aerosolized even between breaths resulting in inefficiency
Solution Approach 1:
The system uses breath-synchronized periodic aerosol generation where the aerosol generator is activated only during detected inhalation events. This eliminates continuous aerosolization during exhalation phases, significantly improving medicament delivery efficiency and reducing waste
Solution Approach 2:
The system incorporates breath detection feedback to control aerosol generation timing. Breath sensors detect inhalation events and trigger aerosol release, creating a closed-loop control system that synchronizes medicament delivery with patient breathing patterns
3Productivity
If aerosol generator is positioned far from patient interface, then airflow patterns are stable, but aerosol delivery efficiency to the lungs is reduced
Solution Approach 1:
The patent creates localized optimal conditions by positioning the aerosol generator 2-8 cm from the patient interface, creating a focused aerosol delivery zone. The aerosol chamber design provides local turbulence and mixing only where needed while maintaining stable airflow elsewhere in the system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly enhances surfactant delivery efficiency to the lungs, achieving higher and more consistent inhaled doses compared to conventional methods, with improved safety and reduced side effects.
Implementation Method 1
aerosolizing, using the aerosolization device, a volume of medicament into particles having a mass mean aerodynamic diameter (MMAD) of less than about 3 µm at a rate of at least 0.1 ml/min
Implementation Method 2
The at least one baffle may be configured to divert a first portion of airflow from the inspiratory limb to the expiratory limb and to divert a second portion of airflow into the aerosol chamber via the at least one airway
Implementation Method 3
at least one breath sensor that is configured to detect an inhalation of the infant and a controller that is configured to synchronize the aerosolization of the volume of surfactant with the detected inhalation
Data Source
Figure 1
Figure 1A
Figure 2
AI summary
A method of delivering aerosolized surfactant to an infant that includes interfacing an aerosolization device with an airway of an infant and aerosolizing, using the aerosolization device, a volume of surfactant into particles having a mass mean aerodynamic diameter (MMAD) of less than about 3 µm at a rate of at least 0.1 ml/min. The surfactant is aerosolized within about 1 to 8 cm from a patient interface. Aerosol is generated for up to approximately 80% or each inspiration. The method also includes delivering the aerosolized surfactant to the infant's airway.